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ABSTRACT
Content and Activity of Cytochrome P450 3A in Rat Brain
Microsomes and Mitochondria.
by: Nouf Alshammari
The potential contribution of CYP3A in brain microsomes and mitochondria is crucial to designing
appropriate therapeutic strategies and preventing toxicities. Until recently, there has been limited
data reported in the literature with respect to CYP3A activity and its expression in the brain tissue.
The reason for this limitation is most likely the relatively low level of CYP3A in the brain tissue.
To this end, the primary purpose of this study is to develop a CYP3A functional assay in rat brain
mitochondria and microsomes to determine the Michaelis-Menten kinetics of the formation of
CYP3A-mediated hydroxylated metabolites of midazolam by UPLC-MS/MS. We also aim to
analyze the protein levels of CYP3A in the rat brain mitochondria and microsomes by Western
blot analysis.
Microsome and mitochondria were prepared using different centrifugation methods, followed by
purification of the crude mitochondrial fractions using the Percoll density gradient method. The
purity of the fractions was determined by Western blot analysis of the microsomal (calreticulin)
and mitochondrial (VDAC) markers. Different concentrations of midazolam were incubated with
rat brain microsomes and mitochondria in a side-by-side comparison over a period of 10 minutes.
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The method was developed and optimized to determine the Michaelis-Menten kinetics of MDZ
1′- and 4-hydroxylase activities in rat brain microsomes and mitochondria (n=8). For 4hydroxymidazolam, brain mitochondria had 2.5-fold higher maximum velocity and 5-fold higher
MM constant compared to microsomes. For 1’-hydroxymidazolam, mitochondria had 9-fold
higher maximum velocity and 153-fold higher MM constant compared to microsomes.
Consistent with the higher Vmax of the metabolites in the mitochondrial fractions, the Western
blot analysis showed higher band intensities related to CYP3A2 in the brain mitochondria, when
compared with the brain microsomes. Our in vitro study indicates that in the brain the content
and activity of CYP3A in the mitochondria are higher than those in the microsomes, an
observation which is opposite of the pattern reported in the liver. The local metabolism of
CYP3A substrates in the brain microsomes and mitochondria may have significant ramifications
for the effectiveness or toxicity of the centrally-acting drugs that are CYP3A substrates.
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CHAPTER 1
Introduction
1.1.1

Cytochrome P450 enzyme

The human body has a unique system of enzymes that helps it eliminate various toxins. The study
of CYP enzymes has increased dramatically over the last decade, owing to their essential role in
response to therapeutic drugs and drug toxicity. Cytochrome P450 (CYP) enzymes are a
superfamily of heme-containing monooxygenases (mixed-function oxidases), which catalyzes a
variety of reactions involved in the metabolism of substances and the biosynthesis of cholesterol,
steroids, and other lipids (Nelson, 2005). Because most medications are extremely lipid soluble
and nonpolar and hence difficult for the kidney to remove, the majority of lipophilic compounds
are transformed to much more polar/hydrophilic molecules that can be eliminated in the urine
(Donato and Castell, 2003). This conversion occurs via a process known as biotransformation,
which converts lipophilic chemicals into more hydrophilic metabolites that are more easily
excreted in the urine or bile. Metabolic reactions are classified into phase I and phase II Fig. 1
(Kennedy and Tierney, 2012).
Phase I metabolic pathway is mostly oxidative in function and result in the formation of
metabolites that are more polar than their precursor compounds. The purpose of phase I
biotransformation is to increase the compound's polarity by exposing the functional group (e.g., OH, -NH2, -SH) on the medication (Jancova et al., 2010). Phase II involves conjugating the drug
or its metabolites to endogenous molecules, such as glucuronidation, sulfation, methylation,
acetylation, glutathione, and amino acid conjugation. When compared to nonconjugated
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molecules, conjugates tend to be significantly more water-soluble and, in most cases, substantially
less active, therefore, less poisonous (White, 2017). They are produced by transferring a specific
moiety from a coenzyme to either endogenous or exogenous substrates. The enzymes are
commonly referred to as transferases, including UDP-glucuronosyltransferases, sulfotransferases,
N-acetyltransferases, glutathione S-transferases, and various methyltransferases (thiopurine Smethyl transferase and catechol O-methyl transferase).

Figure 1 Biotransformation pathways: phase I and Phase II

1.1.2

The nomenclature of cytochromes P450

Based on amino acid sequence identity, enzymes are classified into families, subfamilies, and
isoforms Fig. 2. An isoform is a CYP enzyme variant that derives from one specific gene. In the
recent decade, extensive efforts have been made to classify CYP enzymes based on the nucleotide
sequence homology of CYP genes (Nelson et al., 1996). This nomenclature classification is
currently widely used and allowed the CYP gene superfamily to be divided into families and
subfamilies with the prefix CYP used to designate cytochrome P450 in all species (Table 1). All
CYP families have 40% homology in amino acid sequences. A subfamily with a capital letter
2

contained an enzyme with 55% amino acid sequence homology (Bibi, 2008). The Isoenzyme is
represented by an Arabic numeral. Figure 3 depicts an example of cytochrome P450 enzyme
nomenclature.

Figure 2 Cytochrome P450 enzymes in families 1 – 3

Figure 3 An example of the nomenclature of the cytochrome P450 enzymes (Wijnen et al., 2007).
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Table 1 Cytochrome P450 families and subfamilies in rats and humans.

Family

Subfamily

CYP1

A

B

CYP2

A

Rat enzyme

Human enzyme

1A1

1A1

1A2

1A2

1B1

1B1

2A1

2A6

2A2

2A7

2A3

2A13

2B1
B

2B6

2B2
2B3
2B12
2B21

C

2C6

2C8

2C7

2C9

2C11

2C10

2C12

2C18

2C13

2C19

2C23
2C24

4

D

2D1

2D6

2D2

2D7P

2D3

2D8P

2D4
2D5
2D18
CYP3

2E1

2E1

3A1

3A4

3A2

3A5

3A9

3A7

3A18

3A43

E

A

3A23

(http://drnelson.utmem.edu/CytochromeP450.html)

OR

(http://drnelson.uthsc.edu/human.P450.table.html).

1.1.3

Basic features of cytochrome P450 enzymes

These enzymes are reported in the endoplasmic reticulum membranes of cells, primarily in the
liver. The first report of the presence of a carbon monoxide-binding pigment in rat liver
microsomes was made in 1958 (Klingenberg, 1958;Garfinkel, 2003;Cederbaum, 2015). When
reduced, the pigment exhibited maximum absorbance at 450 nm during its bounding to carbon
monoxide and was designated P (pigment)-450. P450 accounts for most hemoproteins detected in
liver microsomes (Omura and Sato, 1964). CYP enzymes are also active in several other tissues
such as the kidney, small intestine, lungs, adrenal cortex, skin, brain, testis, and placenta. With the
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highest concentrations found in liver microsomes (where it plays a major role in detoxification
reactions) (Omura et al., 1965).
Thomas L. Poulos. (1987) discovered the three-dimensional structure of cytochrome P450. This
discovery establishes the enzyme's binding sites for two molecules: one of oxygen (O2) at its heme
group and another molecule (the substrate) right above the heme group. Alpha helices and beta
sheets are formed when the constituent amino acids' structures are twisted (Guengerich, 1993).
The active site of cytochrome P450 is a heme-iron center. The iron is bound to the protein via a
cysteine thiolate ligand. An example of the three-dimensional structure of the CYP2C5 enzyme is
given in Figure 4.

Figure 4 Three-dimensional structure of CYP2C5 enzyme (Thomas M., 2011).

1.1.4

The cytochrome P450 catalytic cycle

P450 acts as a monooxygenase by catalyzing the cleavage of molecular dioxygen and subsequent
insertion of a single oxygen atom into the substrate, resulting in the formation of a water molecule.
The overall catalytic process of mono-oxygenation of a substrate (RH) can be described as follows
(Taniguchi et al., 1984),

6

NADPH+H++O2+RH⇒NADP++H2O+R-OH
RH is an oxidable drug substrate, whereas ROH is the hydroxylated metabolite. NADPH is the
source of the reducing equivalents involved in the transfer of electrons in oxidizing reactions. The
oxygen is added to the drug to form a hydroxyl group, while the other atom of oxygen is converted
to water. These reactions were discovered to occur in specific cell localization. When the cells in
these tissues are homogenized, the endoplasmic reticulum within the cell membrane fragments
into small vesicles known as microsomes (microsomal CYP450). P450 enzymes have also been
found in mitochondria, and a novel Mitochondrial P450 was purified from adrenal cortex tissues
for the first time in 1964 (Harding et al., 1964) and later in other steroidogenic organs of animals
(Omura, 1999). Mitochondrial P450s are integral membrane proteins that are firmly attached to
the inner membrane of the cell. Their primary role is to metabolize endogenous and exogenous
compounds.

1.1.5 Electron transfer to P450
Based on the nature of the electron transfer proteins, CYPs can be classified into microsomal and
mitochondrial P450 systems, as summarized in Table 2. (Koymans et al., 1993; Cederbaum, 2015)
Table 2 microsomal and mitochondrial P450 electron transfer systems

System

Electron transfer chain

Mitochondria

NADH + FAD + Fe2S2+ P450

Microsome

NADPH+FAD+FMN+P450
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The presence of molecular oxygen, NADPH, and a mixed-function oxidase is required for
oxidation processes (cytochrome P450, NADPH- cytochrome P450 reductase). For microsomal
and mitochondrial CYP450, NADPH is the preferable reductant for introducing molecular oxygen
into the substrate and generating the hydroxyl group. Primary electron transport to P450 occurs
via a NADPH-dependent oxidoreductase including flavoprotein (FAD and FMN). A flavoprotein
is composed of a flavin group attached to an adenosine diphosphate to generate flavin adenine
dinucleotide. FAD and FMN are critical cofactors for microsomal P450 heme reduction, as P450
cannot take electrons directly from NADPH. Thus, electrons are transferred from NADPH to the
FAD, which then transfers electrons to FMN via CYP450 Reductase (CPR) to reduce P450's heme.
CPR is required for microsomal P450 activation. Without CPR, microsomal CYP450 cannot be
induced. In contrast, mitochondrial P450 utilizes two soluble proteins found within the matrix of
mitochondria: Adrenodoxin (is a ferredoxin-type-iron-sulfur protein) and adrenodoxin reductase
(is a FAD- containing flavoprotein). Adrenodoxin reductase transfers electrons from NADPH to
FAD, thereby reducing the adrenodoxin iron-sulfur protein and, subsequently, heme iron of
mitochondrial P450 (Fig. 5).

Figure 5 Inner mitochondria membrane and endoplasmic reticulum membrane
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Mitochondrial CYP450(A); Adrenodoxin reductase transfers electrons from Flavin Adenine Dinucleotideto
adrenodoxin (ferredoxin) and then to the heme iron of P450. Microsomal CYP450(B); CYP450 Reductase (CPR)
transfers electrons to Flavin Adenine Dinucleotide, then to Flavin Mononucleotide (FMN), and then to the P450 heme
iron.
https://www.researchgate.net/figure/Cytochrome-P450-redox-systems-A-The-mitochondrialredox-chain-belongs_fig3_318861050

1.1.6

Contribution of CYP450 in drug metabolism

Drug development is an extensive and complicated process involving the identification of the
characteristics of a drug candidate to evaluate the safety and efficacy of the drug. Considerable
information about the metabolism and other properties of a drug candidate is required before
administering it to a human subject for the first time. Some of the characteristics generally
examined for a new chemical entity is metabolic identification of metabolites, enzymes catalyzing
metabolic routes and the affinity of a chemical for CYP or other enzymes. Although many CYP
genes in humans and rodents play a role in the metabolism process, the metabolism of xenobiotics
is mostly regulated by the first three gene families (i.e., CYP1, CYP2, and CYP3). The following
table. 3 summarizes the most important features of the major drug metabolism enzymes (CYP1-3)
(Ingelman-Sundberg, 2004).
The CYP3A subfamily of enzymes is the most abundant CYP that is constitutively expressed in
the adult human liver, and it contributes to the elimination of the majority of all therapeutic agents
now in use (Bertz and Granneman, 1997; Krishna and Shekar, 2005) Fig. 6. CYP3A is also present
in many extrahepatic tissues, including the intestine, kidney, lung, adrenal gland, prostate, and
brain (Finnström et al., 2001; Hedlund et al., 2001; Raunio et al., 2005; Woodland et al., 2008;
9

Venkatapura Chandrashekar and Mehvar, 2020). In humans, the CYP3A enzyme is found in four
isoforms, namely, 3A4, 3A5, 3A7, and CYP3A43(Nelson et al., 1996). Immunoblotting studies
indicate that CYP3A4 is highly expressed in the liver and intestine. (Wrighton and Stevens, 1992;
Paine et al., 2006). It is also highly inducible by a variety of drugs and other chemicals. Its
inducibility is similar to that of the drug transporter P-glycoprotein (P-gP) in the intestine. The
genes are located on chromosome 7q21.1 and seem to use comparable DR4 regulatory elements
for binding. Pregnane X receptor (PXR) is a nuclear receptor that primarily detects and upregulates
the production of proteins in response to the occurrence of external toxic substances. Due to
CYP3A4's broad substrate specificity and its ability for xenobiotic metabolism, as well as its coregulation with the drug transporter P-gP, which is found in abundance in the intestine, these two
components form the most significant unit for xenobiotic clearance in the body (Geick et al., 2001).
Hence, CYP3A4 plays a part in the metabolism of a large number of medications. CYP3A4 and
CYP3A5 have identical nucleotide sequences and antibodies against CYP3A4 frequently crossreact with CYP3A5 (Belloc et al., 1996). Nevertheless, CYP3A4 is more active than CYP3A5 in
most CYP3A substrates and is expressed at much lower levels in the liver than CYP3A4 (WestlindJohnsson et al., 2003).
CYP3A7 is strongly expressed in the liver during the early development of a fetus, whereafter its
expression declines to almost untraceable levels, and CYP3A4 levels rise to adult hepatic content
(Schuetz et al., 1994) (de Wildt et al., 1999). CYP3A7 metabolizes many of the substances
metabolized by CYP3A4 but with significant activity differences. The expression of CYP3A43
mRNA is low at about 0.1% of CYP3A4 in human liver samples. However, CYP3A43 expression
is relatively higher in the brain (Agarwal et al., 2008). Although it is technically acceptable to use
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“CYP3A” to indicate the expression or activity of any of the four isoforms, it must be noted that
CYP3A4 and CYP3A5 are the two most predominant isoforms in adult humans.

Figure 6 Contribution of CYP450 in drug metabolism.
https://www.oatext.com/Genetic-polymorphisms-of-drug-eliminating-enzymes-and-transporters.
Table 3 General characteristics of CYP1-3 in human

Enzyme

Marker-substrate

Substrate specificity

reaction

CYP1A1

EthoxyresorufinO-

Main
localization

Pre-carcinogens

Extrahepatic

Aromatic, amines

Liver

deethylation

CYP1A2

PhenacetinOdeethylation.
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tissue

ethoxyresorufinOdeethylation

CYP1B1

Estradiol-4-

oestradiol

Extrahepatic

hydroxylation

CYP2A6

Coumarin

7- Nicotine

Liver

7-

Olfactory

hydroxylation

CYP2A13

Coumarin
hydroxylation

CYP2C8

Taxol hydroxylation

CYP2C9

Tolbutamide

mucosa

Liver

Drugs

methylhydroxylation,

12

Liver

losartan
hydroxylation,

S-

warfarin

7-

hydroxylation

CYP2C19

S-mephenytoin4-

Drugs

Liver

Drugs

Liver

Chlorzoxazone6-

drugs,

pre- Liver

hydroxylation

carcinogens

hydroxylation,
omeprazole5hydroxylation

CYP2D6

DextromethorphanOdeethylation,
bufuralol

1’-

hydroxylation,
debrisoquine4hydrohylation

CYP2E1

13

CYP2F1

Not known

CYP2J2

Arachidonic

Not known

Lung

acid Fatty acids

Extrahepatic

D25 Vitamin D

Extrahepatic

hydroxylation

CYP2R1

Vitamin
hydroxylase

CYP2S1

Trans-retinol

Small aromatic

oxidation

CYP3A4

hydrocarbons

Testosterone6b-

Drugs

hydroxylation,
midazolam

Extrahepatic

1’-

hydroxylation,

14

Liver, intestine

erythromycinNdemethylase

CYP3A5

Testosterone6b-

Drugs

Liver, intestine

6b- Drugs

Liver, intestine

hydroxylation,
midazolam

1’-

hydroxylation,
erythromycinNdemethylase

CYP3A7

Testosterone
hydroxylation,
midazolam

1’-

hydroxylation,
erythromycin

N-

demethylase

CYP3A43

Not known

Not known

15

Not known

1.1.7

CYP3A enzyme in the brain

It is well established that cytochrome P450 (CYP) 3A enzymes play an important role in drug
metabolism in humans. Their function in the liver and intestinal tissues has been extensively
studied. However, their expression and functional activity in the brain are not clearly understood.
Studies conducted on both humans and rodents have shown that both species contain several
different CYP enzymes, including CYP3A, in the brain (Woodland et al., 2008; Kuban and Daniel,
2021). These enzymes also metabolize a number of psychoactive drugs and may significantly
impact the efficacy and safety of the drugs. Even though the CYP isoforms in the liver and the
brain are almost alike, there may be functional changes between the two (Miksys and Tyndale,
2002). Local brain metabolism of drugs at their site of action may affect therapeutic efficacy
differently from liver metabolism, and this difference leads to diversity in the brain-drug response.
Moreover, the CYPs subcellular localization of the brain differs from the hepatic CYPs due to
variation

in

cellular

structures

of

hepatocytes

and

neurons.

Immunoblotting

and

immunohistochemistry research findings on whole brains of rats show that the expression of total
CYP enzymes in the brain is only about 10% of that in the liver (Warner et al., 1988; Gervasini et
al., 2004). The studies indicated that CYP3A is found in the cerebellum, olfactory bulbs,
hypothalamus, and striatum of the rat brain. It was found that the total mRNA level of Cyp3a1 in
the rat brain was only 0.02% of that in the rat liver (Schilter and Omiecinski, 1993).
Notwithstanding these low levels, various drugs used to treat central nervous system (CNS)
conditions are CYP3A substrates, and their action in specific areas of the brain may cause
therapeutic failure or drug-induced toxicity. Furthermore, studies have found CYP3A enzyme
isoforms in the mitochondrial and microsomal fractions of several brain parts in both rats and
humans. It was found that microsomes from rats contained small amounts of 6-hydroxy
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testosterone after testosterone incubation (Jayyosi et al., 1992). It is hypothesized that the enzyme
CYP3A is responsible for the conversion of testosterone to its 6-hydroxylated metabolite. The
author also discovered a significant immunoreactive band in the brain mitochondria and a minor
band in the brain microsomes. Compared to the microsomes, the considerably predominant band
in the mitochondria was linked with 40% lower 6-hydroxy testosterone formation in the
mitochondria. Moreover, the anti-cytochrome P450p antibody did not impact the 6-hydroxy
testosterone production. Therefore, the research could not ascertain CYP3A activity in the rat
brain, and the effect of cytochrome P450p-related immunoreactive protein in rat brain
mitochondria must be studied further.
Using Western blot analysis, Rosenbrock et al. (1999) showed that CYP3A was present in
substantially lower amounts in the brain microsomes than in the liver microsomes. They were also
able to detect relatively low amounts of 6b-hydroxy testosterone after long incubation times of 2–
6 h. The production of 6b-hydroxy testosterone was induced by five times after a 3-week oral
treatment with phenytoin. However, inhibitory experiments with the anti-CYP3A antibody
lowered the formation of 6b-hydroxy testosterone only marginally (8%), whereas the antiCYP2B1/2 antibody decreased the formation of the metabolite at a much higher level (35%). Based
on these experiments, it can be suggested that 6b-hydroxylation of testosterone in the rat brain is
not a suitable analysis for determining CYP3A activity in the rat brain. Certain immunoblotting
investigations indicate that the presence of Cyp3a1/2 protein is substantially more in the brain
mitochondrial fraction than in the microsomal fraction contrary to what is observed in the liver
(Jayyosi et al., 1992).
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A Northern blotting experiment revealed that Cyp3a9 is transcriptionally expressed in the rat brain
(Wang et al., 1996). The inducibility of Cyp3a9 was by using dexamethasone. However, the
blotting analysis revealed no substantial increase of CYP3A9 mRNA in rat brain when
dexamethasone was used. This finding supported Jayyosi et observation that testosterone
metabolism by rat brain microsomes was not inducible. Furthermore, fluorescence in situ
hybridization was performed to show the existence of Cyp3a mRNA in neuronal cells of the rat
cortex, cerebellum, hippocampus, and thalamus (Pai et al., 2002). Recently, the expression of
Cyp3a1 mRNA, but not Cyp3a2 mRNA, was confirmed in male rat brain micro-vessels by RTPCR (Mei et al., 2004). All these findings supported the presence of CYP3A in microsome and
mitochondria in the rat brain.

1.1.8

CYP3A activity in the brain

Low levels of CYP expression in the brain prove that the brain plays a minimal role in drug
clearance. However, for medications that can cross the blood-brain barrier, including the functional
barrier created by efflux pumps, CYP-mediated biotransformation may be crucial for their
efficacy, or lack of it (Britto and Wedlund, 1992). Hence, it is essential to understand CYP activity
in different compartments of the brain to optimize medication for many CNS disorders. In addition,
many endogenous and exogenous CYP3A substrates have been shown to be metabolized by brain
fractions prepared from different species including mice, rats, monkeys, and humans (Martignoni
et al., 2006). For instance, the demethylation of amitriptyline to nortriptyline in rat and human
brain microsomes has been shown to be CYP3A-mediated, as seen in its suppression by
ketoconazole and a monoclonal antibody specific for CYP3A4 (Voirol et al., 2000). In an initial
study published in the same article, it was shown that CYP3A4 was the main isozyme to participate
in the metabolism of Midazolam, with only a minimal production of 1-hydroxymidazolam,
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possibly due to reduced sensitivity of the assay. Several studies have shown qualitative variations
in the metabolism of CYP3A between the liver and the brain. For example, the production rate of
two CYP3A metabolites of alprazolam were shown to be different in microsomes taken from entire
brains of rats than in liver microsomes (Pai et al., 2002). As hypothesized, rat liver microsomes
metabolized alprazolam at a much higher rate (30-fold) than rat brain microsomes, but the
difference in the rate of production of the minor metabolite, 1-hydroxyalprazolam (1-OHA), was
much smaller (1.3-fold higher in liver than in brain). It may be therapeutically significant that the
brain generates more 1-OHA than 4-OHA compared to the liver, as 1-OHA is more
pharmacologically active (77% of a parent) than 4-OHA (14% of a parent). Recent research has
explored the catalytic activity of rat Cyp3a1 in the brain using erythromycin as a substrate (Yadav
et al., 2006). Brain microsomes obtained from Wistar rats had 11-fold lower erythromycin
demethylase activity than liver microsomes. Erythromycin demethylase activity increased 3- to 4fold in the liver and 1.5- to 2-fold in the brain following dexamethasone and pregnenolone-16carbonitrile (PCN) pretreatment of rats, but it remained constant following phenobarbital
pretreatment.
•

Use of midazolam as a probe agent for CYP3A phenotyping

Midazolam is a benzodiazepine sedative-hypnotic with a short half-life that the FDA has approved
for use in inducing anesthesia and sedation. Midazolam is metabolized to two primary
hydroxylated metabolites, 1'hydroxymidazolam (1'OH-MDZ) and 4'hydroxymidazolam (4'OHMDZ) by CYP3A4 and CYP3A5 Figure 7 (Jabor et al., 2005). Midazolam has frequently been
used as a probe drug to assess CYP3A function in healthy subjects due to its nearly complete
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metabolism by CYP3A and lack of affinity for transporters, as well as its short half-life and
favorable safety profile (Chaobal and Kharasch, 2005).

Figure 7 Chemical structure of midazolam and its major metabolite.

1.1.9

Implications of P450 on brain cell

The blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier are important
factors for managing the composition of the cerebral environment. The formation of central
nervous system (CNS) barriers prevents many drugs and xenobiotics from entering the brain due
to structural changes, such as the development of tight junctions, which are responsible for this
restriction (Abbott, 2005). The entry of the drug into the brain is controlled by efflux transporters
that are ATP-dependent and membrane-bound, as has been shown in several studies of the BBB
and blood-CSF barrier cells. It has been demonstrated that lipophilic compounds used in CNS
therapy are substrates for drug efflux transporters expressed on the luminal side of the
cerebrovascular system (Marchi et al., 2004). This is one of the processes causing medication
resistance in ailments of the central nervous system. Recent research has found that the P450
enzymes in the brain are also critical in the treatment of psychosomatic disorders. CYP enzymes
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are heme-containing proteins that, along with their involvement in drug metabolism in the liver,
are functionally active in the neurovascular unit and are expressed in other brain cells (Ghosh et
al., 2011).
In contrast to drug transporters, the biotransformation of a parent drug into a metabolite can have
major pharmacological consequences, altering the affinity and final efficacy of a drug on a given
target. The discovery of xenobiotic-metabolizing enzymes in humans has led to the speculation
whether this class of enzymes is involved in the development of illness or not (Dutheil et al., 2008).
Pharmacological reactions in the brain are influenced by drug biotransformation, which may affect
local pharmacological reactions and cause adverse effects. Although CYP levels in the brain are
typically lower than those in the liver, it has been suggested that changes in CYP brain
biotransformation play a role in the failure or toxicity of central nervous system (CNS)
medications. Brain P450 expression may become even more pronounced in the presence of CNS
ailments and cancer.
Epilepsy: Many factors affect antiepileptic medication (AED) efficacy, including drug
metabolism and delivery to the target sensitivity. Recently, it was proposed that neurovascular
P450s have a role in the epileptic brain (Ghosh et al., 2011). Therapeutic efficacy or the
development of neurotoxic metabolites may be lost due to the local metabolization of AEDs. In
human hippocampus pyramidal neurons, AEDs such as oxcarbazepine, carbamazepine, and
phenytoin are associated with CYP3A4 (Killer et al., 2009). Thus, inducing CYP3A4 metabolism
in the brain can potentially change brain function. The localization of CYP3A4 in the microvessels and neurons of a drug-resistant epileptic brain has been demonstrated by using an
immunohistochemistry study. Non-neurological autopsy brain tissues have unexpectedly shown
lower levels of CYP3A4 than drug-resistant epileptic brains. Moreover, previous studies have
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found that CYP3A4 mRNA expression was substantially higher in epileptic brain endothelial cells
isolated from the drug-resistant epileptic brain (Ghosh et al., 2010; Ghosh et al., 2011). Compared
to patients with untreated epilepsy, patients treated with AED have higher expression of CYP3A4
in the hippocampus area (Killer et al., 2009).
Cancer: P450 enzymes’ existence in tumor cells has been linked to tumor formation, the
reason being that specific P450 enzymes perform essential cellular functions such as inactivating
antitumor drugs or activating tumor-promoting drugs (McFadyen et al., 2004). This emphasizes
the key role of CYPs in balancing cytotoxicity and protection. Research has shown that the
concentrations of ellipticine required to kill a glioblastoma cell line are dependent on CYP1A1,
CYP1B1, and CYP3A4-mediated biotransformation, confirming a link between P450s and
anticancer activity (Martinkova et al., 2009).

1.1.10

Interindividual Variability in Cytochrome P450

It has been established that 15–20% of the drug candidate is affected by the polymorphism of
CYP genes (Sikka et al., 2005). Polymorphism of CYPs enzymes is a variation related to changes
in the amino acid sequence of the coding region and is responsible for some of the basal
interindividual variation in P450-mediated metabolism in humans. In the presence of genetic
polymorphism, individuals within a certain group of people are separated into a minimum of two
phenotypes, poor metabolizers (PMs) and extensive metabolizers (EMs), based on their abilities
to metabolize a particular probe drug. When the parent molecule is processed exclusively by the
polymorphic enzyme, poor metabolizers have the insufficient metabolizing ability, generally,
create higher drug concentrations, and may exhibit adverse effects or toxicity. In comparison, EMs
may exhibit subtherapeutic levels at standard doses or may require greater doses to get a
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therapeutic response. If the synthesis of an active metabolite is required for therapeutic action,
PMs may fail, while EMs may have a higher risk of side consequences (Fukasawa et al., 2007).
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AIMS OF THE STUDY
The main purpose of this study is to compare the content and metabolic activity of CYP3A in the
brain microsomal and mitochondrial fractions. To achieve this goal, we developed a CYP3A
functional assay in rat brain mitochondria and microsomes to determine the Michaelis-Menten
kinetics of the formation of CYP3A-mediated hydroxylated metabolites of midazolam, as a
substrate of CYP3A, by UPLC-MS/MS. Additionally, we analyzed the protein levels of CYP3A
in the rat brain mitochondria and microsomes by western blot analysis.

Hypothesis
Brain microsomes and mitochondria contribute differently to the local (brain) metabolism of
centrally acting CYP3A substrates.

Specific aims
•

To establish the Michaelis-Menten kinetics of CYP3A activity in the rat brain microsomes and
mitochondria using midazolam as a substrate probe.

•

To determine the relative abundance of CYP3A protein in the rat brain microsomes and
mitochondria by Western blot analysis.
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CHAPTER 2
2.1 Chemicals and antibodies
Midazolam (MDZ) (1443602) was purchased from Sigma Aldrich. Analytical metabolite standard
solutions for 1’-hydroxymidazolam (H-922) was purchased from Cerilliant and 4hydroxymidazolam (UC431) was purchased from Sigma Aldrich. Stable isotope of 1’hydroxymidazolam d5 (KIT1925) and 4-hydroxymidazolam d5 (H948427) were purchased from
Toronto research chemicals. The primary antibodies, polyclonal CYP3A2 (ab195627),
Calreticulin (Ab92516), and VDAC1 (Ab15895), which are raised in rabbit, were purchased from
Abcam (Cambridge, MA, USA). The secondary antibody, Goat Anti-Rabbit IgG H&L (Ab6721), was
purchased from Abcam. The other reagents and compounds were obtained from commercial
sources.

2.2 Experimental
2.2.1 Animals
Animal studies were approved by the Chapman University Institutional Animal care and Use
Committee. Adult male Sprague-Dawley rats (234-274 g) were purchased from Charles River
Laboratories (Wilmington, MA, USA). The rats were housed in a temperature- and humiditycontrolled room under a 12 h light-dark cycle with free access to food and water. Rats were
anesthetized using isoflurane (induction 3-5% and maintenance 1-3% of isoflurane). After
opening the chest, the whole-body perfusion to remove blood was conducted through perfusion
of the left ventricle using a 22-gauge needle and cold saline (0.9%, w/v) at a flow rate of 25
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mL/min for 8 min., The right atrium was cut to allow the blood to flow out. Then, brains were
collected, snap-frozen in liquid nitrogen and stored at -80C.

2.2.2 Preparation of microsomal and mitochondrial subcellular fractions
The differential centrifugation technique is shown schematically in Figure 8 and described below.
Frozen whole brains (n = 8) from adult rats were weighed and homogenized in an ice-cold buffer
(100 mM Tris, 0.2 mM EDTA, 1.15% KCl, pH = 7.4) at a 1:10 ratio, using 50 mL potter-Elvehjam
tubes, applying ten strokes with a motor-driven Teflon pestle. All subsequent steps were performed
on ice (4°C). Cell debris and nuclei were removed by centrifugation at 1300 g for 5 minutes (run
twice). The supernatants were centrifuged at 21,000 g for 12 minutes to separate the crude
mitochondrial (pellet) and the combined cytosolic and microsomal (supernatant) fractions. The
supernatant was collected into a 70 ml Polycarbonate tube (PC) ultracentrifuge tube and
centrifuged twice at 110,000 g-force for 70 minutes to prepare microsomes. The resulting
microsomal pellet was resuspended and homogenized with Potter-Elvejhem homogenizer in 1.5
ml of storage buffer (100 mM Tris, 0.2 mM EDTA, 1.15% KCl, 20% glycerol, 0.1 mM
dithiothreitol, 22 μM butylated hydroxytoluene, and 0.1 mM phenylmethylsulfonyl fluoride; pH
7.4) and stored at -80°C. The mitochondrial pellet was resuspended in a 15% Percoll solution to
purify the crude mitochondrial fraction. The purification was run on a 15%, 24%, and 40% percoll
gradient in 10 mL PC tubes and centrifuged at 30,700 g-force for 12 min. During centrifugation,
purified mitochondria initially layered on the density gradient will sediment until they arrive at the
region of the gradient where the density of the suspension is equal to their own. Thus, the layer
containing pure mitochondria at the interface of the 24% and 40% Percoll layers were collected
and washed 3 to 4 times with the homogenizing buffer by centrifugation at 21,000 g-force for 12
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minutes. The pellet was resuspended and homogenized with Potter-Elvejhem homogenizer in 0.5
ml of storage buffer and stored at -80°C, until required.

Figure 8 Preparation of Microsome and Mitochondria.
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2.2.3 Protein concentration determination
The concentration of protein in brain microsomal and mitochondrial fractions was determined by
Bicinchoninic acid (BCA) protein assay. Microsomal and mitochondrial samples were diluted to
specific dilutions with 100 mM potassium phosphate buffer (pH 7.4). Bovine serum albumin (0-2
mg/ml) was used to construct the protein standard curve. 25 µl of standards and samples were
assayed in triplicate into 96 wells. 200 µl of BCA working reagent was added to each well and
incubated at 37oC for 30 min. The plate absorbance was measured at 562 nm by the
spectrophotometer (BIO-RAD, iMark, Microplate Reader, Hercules, CA).

2.2.4 Validation of the purity of the subcellular fractions
Calreticulin (Rabbit antibody) was used as a marker for the brain microsomal fractions and
VDAC (Rabbit antibody) was used as a marker for the brain mitochondrial fractions.
Microsomal and mitochondrial samples from 8 rat brains were diluted to 1 mg/ml with 1xTBS.
Loading buffer (100 μl of 2-b-mercaptoethanol and 900 μl of 4x Laemmli sample buffer, BIORAD, Hercules, CA) was added to each sample at a ratio of 3:1 and heated in 95°C water for 5
minutes. Proteins (10 µg) were subjected to SDS-polyacrylamide gel electrophoresis on a precast
Bio-Rad (Hercules, CA, USA) 4-20% MP TGX Stain-Free gels at constant voltage (200 V) for
30 minutes. Proteins were transferred onto PVDF membranes using the Bio-Rad Trans-Blot
Turbo Transfer System; then, the membrane was blocked with 5% BSA for 1 hour at room
temperature. Subsequently, the membrane was incubated overnight with the primary antibody in
a cold room at 4°C: calreticulin (1:10,000), or V-DAC1 (1:50,000). After washing, membranes
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were incubated with the secondary antibody (Abcam, Goat Anti-Rabbit) diluted in wash buffer
with StepTactin-HRP ladder solution (1:50,000) for 1 hour at room temperature on a shaker.
Then, bands are visualized with the Bio-Rad ChemiDoc Imager system. The intensities of
VDAC1 bands in mitochondria and calreticulin bands in microsomes were considered as 100%,
and the percent impurities of VDAC1 in microsomes (mitochondrial contamination) and
calreticulin in mitochondria (microsomal contamination) were subsequently estimated.

2.2.5 Determination of midazolam hydroxylase activity
Base-powder of commercial Midazolam was dissolved in 105 mM HCl to give a stock solution of
5000 μM (50 mM). The primary stock solutions of Midazolam (50 mM) were further diluted with
5 mM HCl to make working solutions of 50, 100, 250, 500, 1000, 2500, 5000, and 10000 μM for
assessing microsome CYP3A enzymatic assay and 250, 500, 1000, 2500, 5000, 10000, 15000,
25000, and 50000 μM for assessing mitochondria CYP3A enzymatic assay. Two independent runs
side-by-side were performed to ascertain the differences between microsome and mitochondria
activities, one set for microsome and the other set for mitochondria. The reaction mixture (25 µL)
in 100 mM Tris-HCl buffer, pH 7.4 (15 µL) contained 0.25 mg/ml rat brain microsomes or
mitochondria (2.5 µL of a 2.5 mg/ml microsomal or mitochondrial suspension), 20 mM Mg Cl2
(2.5 µL of 200 mM stock) and 1 mM NADPH (2.5 µL of 10 mM stock). The mixtures were
vortexed and pre-incubated for 5 minutes, maintained at 37°C. The reaction was initiated by adding
the 2.5 µL of MDZ stock solutions to get the final conc. ranging from 5 to 1000 μM for microsome
and 25 to 5000 μM for mitochondria with an incubation time of 10 minutes. The reaction was
stopped by the addition of 75 μl acetonitrile, containing 10 nM 1’-OH-d5 and 4-OH-d5 as internal
standards. The reaction mixtures were vortexed, placed on ice for 5 minutes, centrifuged for 5
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minutes at 13,400 rpm, and injected onto the LC-MS/MS system. The incubation time of 10 min
and the protein concentration of 0.25 mg/mL were based on previous studies, investigating the
time and protein linearity in microsomes (Devaraj et al., 2021).

2.2.6

Liquid chromatography–mass spectrometry (LC-MS/MS)

2.2.6.1. Instrumentation
The mass spectrometric data for midazolam, metabolites (1’-hydroxymidazolam & 4hydroxymidazolam),

and

their

respective

deuterated

internal

standards

(1’-

hydroxymidazolam-d5 and 4-hydroxymidazolam-d5) were generated using Bruker EVOQ
triple quadrupole mass spectrometer, as described before (Devaraj et al, 2021).
Chromatography was performed on a Kinetex 1.7 μm C18 (100 × 2.1 mm, 100 Å) column
(Phenomenex Inc; Torrance, CA, USA), preceded by a Phenomenex C18 Security Guard
ULTRA (2.1 mm) pre-column. All chromatographic separations were performed at a flow rate
of 0.250 mL/min under gradient conditions described in Table 4. Mobile phase A consisted of
5 mM ammonium formate in LCMS water, and mobile phase B consisted of 100% acetonitrile.
All other LC-MS/MS setting for CYP3A assay are shown in (table 4).
Table 4 LC/MS/MS setting for CYP3A

Column

: Kinetex, C18, 1.7 µm, 100 mm x 2.1 mm

Mobile phase A (aqueous)

5mM ammonium formate in LCMS water

30

Mobile phase B (Organic)

100% Acetonitrile

Column Temperature

400C

Flow rate

0.25 mL/min

Gradient conditions (min)

Mobile phase A
Time (min)

Mobile phase B (%)
(%)

MRM transitions and Retention time

0.00

70

30

1.20

70

30

5.00

30

70

6.00

30

70

6.00

70

30

7.50

70

30

1’-hydroxymidazolam 342 -> 202.9 (quantifier ion)
Retention time = 4.69 minutes
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d5-1’-hydroxymidazolam 346.9 -> 207.9 (quantifier ion)
Retention time = 4.69 minutes

4-hydroxymidazolam 342 -> 233.9 (quantifier ion)
Retention time = 4.4 minutes

d5-4-hydroxymidazolam 346.9 -> 234.9 (quantifier ion)
Retention time = 4.4 minutes

Midazolam 326 -> 290.9 (quantifier ion)
Retention time = 5.5 minutes

Source Conditions:

Source type = Heated Electrospray Ionization (HESI-II)
Spray Voltage = 3000V (positive mode)
Cone temperature = 3000C
Cone gas flow = 25psi
Heated probe temperature = 4000C
Heated probe gas flow = 40psi
Nebulizer gas flow = 50psi
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2.2.7

Stock solution preparation

The primary stock solution of 1’-hydroxy midazolam (metabolite) comes as a 1 mg/mL in
methanol from Cerilliant. This stock’s concentration is 2926 µM, while 4-hydroxy midazolam
solution (metabolite) comes as a solid powder from Sigma. Stock solution of 1 mg/mL is prepared
in methanol and this stock’s concentration is 2926 µM. For the internal standards, the stock
solution of 1’-hydroxy midazolam-d5 solution comes as a 100 µg/mL in methanol from Toronto
research chemicals, stock’s concentration is 289 µM. For 4-hydroxy midazolam-d5 solution, it
comes as a powder from Toronto research chemicals. Stock solution of 2 mg/mL is prepared in
DMSO, and this stock’s concentration is 5780 µM. The primary stock solutions of 1′-OH-MDZ
and 4-OH-MDZ were further diluted with 100 mM Tris-HCl buffer (pH 7.4) to make working
solutions of 10, 20, 50, 100, 250, 500, 750, and 1000 nM for the preparation of calibration curves
and 10, 30, 300, and 800 nM for quality control (QC) samples. The primary stock solutions of the
internal standards were further diluted in acetonitrile to prepare a 10 nM solution.

2.2.8 Preparation of Calibration standards and quality control samples
Calibration standards and quality control samples were prepared in a in the rat brain microsomes
and mitochondria at metabolite concentration range between 1 nM to 100 nM in a final volume
of 25 µL. The calibration standards contained 0.25 mg/mL brain microsomes or mitochondria
and 20 mM MgCl2 in 100 mM Tris buffer pH 7.4. The working solutions of the two metabolites
were added to the matrix to make final concentrations of 0 (blank), 1, 2, 5, 10, 25, 50, 75, and
100 nM for calibration curve standard, and 3, 30, and 80 nM for the preparation of quality
control samples. Then, 75 µL of 10 nM of both 1-OH-MDZ-d5 and 4-OH-MDZ-d5 as internal
33

standards were added to each calibration standard and quality control sample tubes. After vortexmixing, the samples were centrifuged at 13,400 rpm for 5 min. Aliquot (90 µL) of the samples
were transferred into HPLC vials and 5 µL of the sample was injected onto LC-MS/MS.
Calibration curves for each of the two MDZ metabolites were constructed by plotting the peak
area ratios of each analyte: internal standard against the concentrations of the metabolite in the
samples using a weighting factor of 1/x, where × is the added concentration.

2.2.9

Method validation

A partial validation according to the FDA guidelines were performed for quantifying midazolam
metabolites (1’hydroxymidazolam and 4-hydroxymidazolam) in rat brain MC and MT. The
analytical method was validated with respect to accuracy and precision. Three independent runs,
each consisting of a set of calibration standards and three quality control (QC) levels with five
replicates per QC level, were used to verify the assay's precision and accuracy. The QC samples
were prepared similarly to the calibrators and tested at the calibration curve's lower (LQC, 3 nM),
medium (MQC, 30 nM), and higher (HQC, 80 nM) concentrations of both metabolites. On the
same day, five replicates of each QC sample were analyzed against the calibration standards to
determine within-run precision and accuracy. Preparing and evaluating calibration standards and
QC samples in five replicates on three different occasions was used to assess between-run
precision and accuracy. The precision was measured as a percentage of the QC replicates' relative
standard deviation (% R.S.D.). The percent relative error (% R.E.) of the measured concentrations
versus the theoretical concentrations was used to compute the accuracy.
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2.2.10 Western blot analysis of rat brain CYP3A in microsomes and
mitochondria
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was carried out using 4-15% MP TGX
Stain-Free gels with ten well combs (Bio-Rad, 4568096). Microsomal or mitochondrial samples
were diluted to 1 mg/ml concentration with 1x Tris-buffered saline. Laemmli buffer was then
added to each sample at a ratio of 3:1 (sample: buffer). The samples were denatured by heating at
95°C for 5 min. After cooling, the samples were applied to wells of the gel with a protein
concentration of 40 µg. The gel was then electrophoresed at 120 V for 30-90 minutes until the
bromophenol blue had reached the end of the separating gel. Once the gel had finished running,
proteins were transferred onto PVDF membranes using the Bio-Rad Trans-Blot Turbo Transfer
System with constructing a gel sandwich. When the transfer was complete, the membrane was
blocked with 5% nonfat milk prepared in wash buffer (TBS) for 1 hr at room temperature. Then,
the membrane was incubated overnight with the primary antibody against CYP3A (1:2500) in a
4°C cold room on an orbital shaker. We used polyclonal CYP3A2 antibody, which is raised in
rabbit (ab-195627, Abcam). After incubation with the primary antibody, the membrane was
washed and incubated with secondary antibody (1:5000) diluted in wash buffer with StepTactinHRP ladder for 1 hour at room temperature on a shaker. Bands were visualized with the Bio-Rad
ChemiDoc Imager system.

2.3

Statistical Analysis:

The metabolism rate-substrate concentration profiles for microsomal and mitochondrial fractions
were analyzed using a single-enzyme, Michalis Menten kinetics model, including MM parameters
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of maximum velocity (Vmax) and MM constant (Km). The nonlinear regression analysis was
carried out in GraphPad Prism software (La Jolla, CA, USA) using the pooled data from the eight
brains, which generated Vmax and Km values and their variability (SE) for each metabolite (1'OH-MDZ and 4-OH-MDZ) and fraction (microsomes and mitochondria).

The differences

between the microsomes and mitochondria in their MM kinetic parameters were tested using a
two-tailed, t-test analysis. A p-value of < 0.05 was considered significant. All the other data
analyses were performed using Graphpad Prism. Data are presented as mean ± SD.
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CHAPTER 3
3.1

Result

3.1.1 Preparation and Characterization of Microsomes and Mitochondria

3.1.1.1 Protein yields
Based on obtained results from Bicinchoninic Acid (BCA) protein assay, the average (±SD)
protein yields were 7.07 ± 1.19 and 1.88 ± 0.53 mg per g brain tissue for microsomes and
mitochondria, respectively.

3.1.1.2 Marker proteins Calreticulin and Voltage- Dependent Anion Channel
1 (VDAC1)
Western blot analysis using calreticulin antibody as a microsomal protein marker was used to
determine the purity of mitochondria, which corresponds to the MW (48kDa). The results indicated
that 19.3 ± 7.8% of mitochondrial samples were contaminated with microsomes.
VDAC1, a mitochondrial marker with a MW of 31kDa, was used to determine the purity of
microsomal samples. According to this finding, microsomal fractions contained 5.93 ± 3.01%
mitochondrial impurity.
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VDAC1

Expression%

150

100

MC= Microsome

50

MT= Mitochondria

0
MT

MC

Figure 9 Immunoblot analysis of VDAC1, as a mitochondrial marker. Statistical analysis is
based on paired t test. ****P <0.0001

Figure 10 Western blot analysis of VDAC in eight rat brains (MIC=microsome, PM= mitochondria)
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Calreticulin
150
MC= Microsome

Expression%

MT= Mitochondria

100

50

0
MC

MT

Figure 11 Immunoblot analysis of calreticulin as a microsomal marker. Statistical analysis is based on
paired t test. ****P <0.0001.

Figure 12 Western blot analysis of calreticulin in eight rat brains (MIC=microsome, PM= mitochondria).
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3.1.1.3 Western Blot Analysis of CYP3A2
For CYP3A2, an immunoreactive band corresponding to the MW of ~55 kDa was detected in brain
microsomes and mitochondria. Mitochondria exhibited the greatest protein-corrected band
intensity (P <0.0001); band intensities are expressed as a percentage of the intensity. Because
mitochondria had the highest band intensity, the band intensities of CYP3A2 are presented as a
percentage of intensity in the brain fraction of mitochondria. The band intensities of CYP3A2 in
the mitochondria fraction (100 ± 9%) were twice as much as that in the microsomes (49.2 ± 13.3%)
(Fig. 13).

CYP3A2
150

MC= Microsome

Expression%

MT= Mitochondria
100

50

0
MC

MT

Figure 13 Western Blot Analysis of CYP3A2 in eight independent brain samples.
Statistical analysis is based on paired t test. ****P <0.0001
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Figure 14 Western blot analysis in eight rat brains (MIC=microsome, PM= mitochondria).

3.1.2 LC-MS/MS analysis
3.1.2.1

Calibration Curve- linearity

To graph the calibration curve of the drug, each of the two MDZ metabolites were constructed by
plotting the peak area ratios of each analyte/internal standard against the concentration of the
metabolites. As shows in Fig. 15, the calibration curves for both microsome and mitochondria
were evaluated to determine the linearity. As a result, curves are linear and reproducible over
standard concentration range 1-100nM for 1’ and 4 OH MDZ.
A comparison of the calibration curves for microsomes and mitochondria has been performed side
by side. As a result, the slope and r2 values of the microsome and mitochondria calibration curves
are very similar. Therefore, we used only microsome calibration curves to determine CYP3A
Michalis-Menten kinetics in both brain MC and MT samples. Representative coefficient of r2
values and slope calculated in microsome, and mitochondria, are described in table 5 and 6. Fig.
16 and 17 show the chromatograms of blank (0), highest (100nM) and lowest (1nM) concentrations
in the calibration curve.
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Figure 15 Calibration curve of 1’- and 4- OH MDZ, one set containing rat brain microsome
(0.25mg/mL) and other set containing rat brain mitochondria (0.25mg/mL).
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Table 5 4-OH MDZ Slope and coefficient of r2 in microsome (MC) and mitochondria (MT).

Day1

Day2

Day3

MT

MC

MT

MC

MT

MC

Slope

0.01905

0.0177

0.01923

0.0194

0.01817

0.0198

R2

0.9998

0.9997

0.9994

0.9994

0.9996

0.9995

Table 6 1’-OH MDZ Slope and coefficient of r2 in microsome (MC) and mitochondria (MT).

Day1

Day2

Day3

MT

MC

MT

MC

MT

MC

Slope

0.0322

0.0255

0.0318

0.033

0.0315

0.0309

R2

0.999

0.998

0.998

0.999

0.999

0.999
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3.1.2.2

Chromatograms

The spectrometric conditions and other operation parameters were optimized for the detection of
Midazolam metabolites in microsome and mitochondria fractions. The peak shapes of the analyte
were sharp and devoid of any baseline interferences or overlapping peaks (Fig 16 and 17).
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Figure 16 Representative chromatograms of 1-hydroxymidazolam (A, B and C) and 4hydroxymidazolam (D, E and F) generated from rat brain mitochondria in Blank, 1, or 100 (nM)
of 4-hydroxymidazolam and 1-hydroxymidazolam.
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Figure 17 Representative chromatograms of 1-hydroxymidazolam (A, B and C) and 4hydroxymidazolam (D, E and F) generated from rat brain microsome in Blank, 1, or 100 (nM)
of 4-hydroxymidazolam and 1-hydroxymidazolam.
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LC-MS/MS method validation-Precision and Accuracy

Partial method validation was assessed as per the US Food and Drug Administration (FDA)
bioanalytical method validation guidance. The intra- and inter-run accuracy and precision data for
mitochondrial and microsomal samples are presented in Tables 7-10. For mitochondria samples,
the intra- and inter-run R.E. values with respect to 4-OH-MDZ ranged from -8.36% to 9.53% and
R.S.D. values of ≤ 15%. While 1′-OH-MDZ R.E. values ranged from -7.75% to 5.42 and R.S.D.
values of ≤ 15%. For microsome samples, the R.S.D values in both 1’-OH MDZ and 4-OH MDZ
were ≤ 15%. The range of R.E. values were between -7.53% to 15.6% for 1’-OH MDZ and -8.52%
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to 7.74% for 4-OH MDZ. Precision and accuracy values for both intra- and inter-run experiments
were within the acceptable limits in mitochondria and microsome samples.
Table 7 Intra-run precision and accuracy of 4-hydroxymidazolam and 1’-hydroxymidazolam
quality control samples in rat brain mitochondria.

Mitochondria 4-OH
Days

Intra-run (n=5)

Mean

Precision (%R.S.D)

Accuracy (%R.E.)

1

3nM

2.92

6.19

-2.45

2

3.02

6.08

0.617

3

2.74

7.35

-8.36

30.6

6.08

2.15

2

31.0

2.4

3.20

3

32.5

5.83

8.20

84.7

3.37

5.87

2

85.4

3.76

6.83

3

87.6

4.42

9.53

1

1

30nM

80nM

Mitochondria 1-OH
Days

Intra-run (n=5)

Mean

Precision (%R.S.D)

Accuracy (%R.E.)

1

3nM

2.85

2.23

-4.90
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2

3.13

3.21

4.35

3

2.76

3.52

-7.75

30.3

3.08

1.13

2

30.9

3.29

2.91

3

29.6

6.75

-1.37

82.8

0.956

3.52

2

84.3

1.36

5.42

3

79.7

2.46

-0.331

1

30nM

1

80nM

Table 8 Intra-run precision and accuracy of 4-hydroxymidazolam and 1’-hydroxymidazolam
quality control samples in rat brain microsome.
Microsome 1-OH
Days

Intra-run(n=5)

Mean

1

3nM

3.47

9.03

15.6

2

3.03

5.55

1.04

3

2.77

3.52

-7.53

30.8

6.65

2.68

2

29.8

3.14

-0.522

3

30.5

2.16

1.51

87.1

2.13

8.90

2

76.8

2.17

-3.97

3

84.0

1.32

4.96

1

1

30nM

80nM

Precision(%R.S.D)

Accuracy (%R.E.)

Microsome 4-OH
Days

Intra-run (n=5)

Mean

Precision(%R.S.D)

Accuracy (%R.E.)

1

3nM

3.23

5.89

7.74

3.04

4.95

1.20

2

47

3

2.74

1.01

-8.52

33.4

10.6

11.4

2

30.7

2.17

2.24

3

29.6

1.95

-1.47

85.1

3.63

6.37

2

79.7

2.86

-0.377

3

83.4

1.76

4.19

1

1

30nM

80nM

Table 9 Inter-run precision and accuracy of 4-hydroxymidazolam and 1’-hydroxymidazolam
quality control samples in rat brain mitochondria.

4-OH mitochondria
Inter-run

Mean

Precision R.S.D

accuracy R.E.

3nM

2.90

7.24

-3.40

30nM

31.4

5.38

4.52

80nM

85.9

3.89

7.41

1-OH mitochondria
Inter-run

Mean

Precision R.S.D

accuracy R.E.

3nM

2.92

6.18

-2.77

30nM

30.3

4.65

0.900

80nM

82.3

2.87

2.87
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Table 10 Inter-run precision and accuracy of 4-hydroxymidazolam and 1’-hydroxymidazolam
quality control samples in rat brain microsome.

4-OH Microsome
Inter-run

Mean

Precision R.S.D

accuracy R.E.

3nM

3.00

8.16

0.14

30nM

31.2

8.22

4.04

80nM

82.7

3.83

3.40

1-OH Microsome

3.1.3

Inter-run

Mean

Precision R.S.D

accuracy R.E.

3nM

3.09

11.5

3.03

30nM

30.4

4.35

1.22

80nM

82.6

5.68

3.30

CYP3A Michalis-Menten Kinetics

Figure 18 represents the formation rate of 1’-hydroxymidazolam (1’-OH) and 4hydroxymidazolam (4-OH) in eight independent brain microsome and mitochondria fractions.
Fractions were described by the single-enzyme, Michaelis–Menten model. Multiple enzymes were
detected in mitochondria. However, due to a lack of sufficient data points to adequately estimate
the parameters of a multi-enzyme system, we applied the simpler single-enzyme model to describe
mitochondria fraction data. The metabolic rate of 1’ and 4-OH MDZ in microsome fractions
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plateaued between substrate concentrations of 500 and 1000μM. However, the rate of Midazolam
metabolites in mitochondria plateaued at 5000 µM.
Michalis-Menten parameters, maximum velocity (Vmax) and Michaelis-Menten constant (Km)
were determined by non-linear regression analysis. Microsomes contained significantly less
CYP3A activity. When compared to mitochondria, the 4-hydroxylated metabolite had a 2.5-fold
greater maximum velocity (Vmax). In addition, the maximum velocity (Vmax) of the 1'hydroxylated metabolite was 9-fold greater in mitochondria than in microsomes, and the KM
values were 153 times more in mitochondria than in microsomes as well (Table 11 and 12).
Table 11 Maximum velocity (Vmax) and Michaelis-Menten constant (KM) values (mean ±
SD, n = 8 brains) of 1’-OH midazolam metabolites in rat brain microsomes and mitochondria.

1-OH MDZ
Parameters

Microsome

Mitochondria

Vmax***

0.283 ± 0.022

2.56 ± 0.67

Km*

21.7 ± 15.0

3330 ± 1640

***, p < 0.001; *, p < 0.047; Two-tailed, t-test.
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Table 12 Maximum velocity (Vmax) and Michaelis-Menten constant (KM) values (mean ± SD,
n = 8 brains) of 4-OH midazolam metabolites in rat brain microsomes and mitochondria.

4-OH MDZ
Parameters

Microsome

Mitochondria

Vmax*

11.4 ± 2.0

28.8 ± 8.2

Km

574 ± 204

2790± 1540

*, p < 0.05; Km, p > 0.05; Two-tailed, t-test.

4-OH MDZ in Microsome

1-OH MDZ in Microsomes
10

Formation Rate
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Figure 18 Average rate of 4-hydroxymidazolam and 1’-hydroxymidazolam in mitochondrial and
microsomal samples versus different concentrations of midazolam in eight brain preparations.
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CHAPTER 4
4.1
4.1.1

Discussion
Content and activity of CYP3A in brain mitochondria and microsome

This study was undertaken to characterize the CYP3A involved in Midazolam metabolism to its
metabolites: 1’-hydroxymidazolam and 4-hydroxymidazolam, and thus Michaelis-Menten kinetics
of the formation of the metabolites were estimated. Despite the presence of significant quantities
of this enzyme in mitochondria (Jayyosi et al., 1992), the enzymatic activity of CYP3A in brain
mitochondria has not been identified.
Investigating the kinetics parameters of mitochondria and microsome is important to understand
the CYP activity in various brain compartments for optimizing the pharmacotherapy of CNS
conditions. Therefore, the study's main goal was to compare the catalytic activity and
immunoblotting of CYP3A side by side between the endoplasmic reticulum (microsome) and
mitochondria using Midazolam as a substrate probe. The findings suggest that the CYP3A
mediated- enzymatic activity as well as immunoblotting in the brain between mitochondria and
microsome differed markedly. Generally, correlations were established between the Vmax and the
immunoblotting result. The CYP3A enzyme is less active and has a lower content in microsomes,
whereas it is more active and has a higher content in mitochondria. In addition, these results agree
that apparent Km represents the substrate affinity of isoenzyme, whereas apparent Vmax
represents the capacity, which depends on enzyme quantity. Microsomes had a substantially lower
Vmax value than mitochondria. Similarly, the microsome's Km values were much lower than
52

mitochondria. There was low apparent Km (high affinity) and low apparent Vmax (low capacity)
in the metabolic activity of microsome. In contrast, mitochondria showed high apparent Km (low
affinity) and high apparent Vmax (high capacity). The revelations in mitochondria would be
helpful to design appropriate therapeutic strategies and prevent toxicity.
Possible explanations for the metabolic rate differences between microsome and mitochondria
should be divided into two parts for discussion: differences in the electron transfer system in the
subcellular fractions and/or cytochrome P450 isoform activities. The main factor contributing to
low affinity in mitochondria might be related to the electron transfer system in eukaryotic cells,
including adrenodoxin (Adx), which functions as an electron donor in all mitochondrial
cytochrome P450. Wada and Waterman (1992) determined that the adrenodoxin binding site of
mitochondrial P450s involved basic amino acid, position 377 and 381 of bovine P450, which are
exclusively conserved among all mitochondrial P450s but not among microsomal P450s.
According to their results, substituting amino acids at these positions led to dramatic decreases in
affinity for adrenodoxin. In addition to their substantial differences in localization, mitochondrial
P450s differ from their microsomal counterparts in terms of substrate specificity and structural
properties, as well as in respect of their enzymatic activity. Therefore, the differences between
microsome and mitochondria could also be due to the choice of probe and the involvement of more
than one isoform of CYP3A. For instance, it has been reported that 3-methylcholanthrene
selectively increased the high-affinity component of Phenacetin O-deethylase activity in rat liver
microsomes. In contrast, phenobarbital selectively increased the low-affinity component (Kahn et
al., 1987). For this reason, it is necessary to clarify CYP isoform-specificity for these activities in
the rat brain.
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In Western blot analysis, the level of expression of CYP3A2 in mitochondria showed very intense
bands compared to microsome. This is in agreement with the data reported by Jayyosi et al. The
CYP3A1/2 enzyme is present at much higher levels in the brain mitochondrial fraction than in the
microsomal fraction in contrast to what is observed in the liver. In general, there is limited
availability data reported about isoforms of Cyp3a in rat brains. It can be challenging to predict
CYP3A expression and activity. This is due to the low levels of CYPs expressed in the brain dictate
that many studies fail to detect CYP protein.
Midazolam hydroxylation MM kinetics have been reported in rat brain microsomes, but not
mitochondria (Devaraj et al, 2021). We observed that the kinetics of microsomal formation of 4hydroxymidazolam in our study were relatively comparable to the previously published data.
However, the formation rates of 1’-hydroxymidazolam in our study were significantly lower than
the values were reported earlier. The variation in microsomal activity observed in 1’OH MDZ data
could be due to methodological differences between the two studies. For example, in the current
study, we used the BCA assay for the estimation of microsomal and mitochondrial protein levels,
whereas in the previous study, the Bradford assay was used. Bradford is a convenient and simple
assay; however, some of its disadvantages include the nonlinearity of its standard curve, and a
significant protein-to-protein variation (Olson & Markwell, 2007). This results in greater error
rates and coefficients of variation (CV) values when compared to BCA assays. One of the BCA
protein assay’s strengths is its low protein-to-protein variability. Also, it has the advantage of not
interacting with as many contaminants and buffers components, particularly detergents (Olson &
Markwell, 2007).
The current findings highlighted the fact that the activity and content of microsomes and
mitochondria are varied. The results presented in the previous chapter provide an evidence that
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there is a major difference between microsome and mitochondria with respect to the content and
activity. In addition, these data show that the method is accurate and reproducible to quantitate the
midazolam metabolites in brain microsome and mitochondria fractions.

4.1.2

Subcellular fraction purity

Some contamination will inevitably occur in the various subcellular fractions obtained during the
differential centrifugation method. Therefore, we used VDAC1 as a mitochondrial marker and
calreticulin as a microsomal marker. VDAC1 is used to determine the contamination of
microsomes by mitochondria, and calreticulin is used to measure the contamination of
mitochondria by microsomes. Based on the presence of VDAC1, as expected, the intensity of the
antibody reactive bands was higher in mitochondrial proteins. These results suggest that
mitochondrial preparation used in this study contains 19.3% contaminating microsomal fragments,
which is a low but significant level of contamination. In addition, there was a 6.03% contamination
with mitochondria in the microsomal samples, which is consistent with the previous study from
our laboratory (DuBois et al., 2019).
The cytochrome P450 (P450) enzymes are mostly found in the endoplasmic reticulum (ER), where
they function as components of catalytic complexes that metabolize xenobiotics and some
endogenous substrates. However, certain members of families CYP1–3 was discovered in
additional subcellular compartments, including mitochondria. Although the physiological impact
of this finding is unknown in the literature. Thus, it is critical to understand the molecular
mechanisms by which P450s are targeted to these fractions.
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CHAPTER 5
5.1 Conclusion
Studying CYP3A expression and activity in the brain is challenging because of the relatively low
content of CYP activity in the brain and its regional localization. Despite this, CYP3A has been
identified in microsome and mitochondria. The kinetics of midazolam activity in microsomal and
mitochondrial fractions revealed a low affinity, high-capacity enzyme in the mitochondria with a
Vmax and Km higher than in the brain microsomes.
In western blot analysis, the content of CYP3A protein was more intense in mitochondria
compared to microsome. However, the affinity was higher in microsomal samples than
mitochondrial fractions.
The ability of CYP3A enzymes in the brain to metabolize several endogenous and exogenous
compounds suggests that they may affect the activity and fate of CNS drugs. However, the extent
to which individual CYP3A isoforms contribute to this biotransformation remains to be
elucidated. To optimize pharmacotherapy with such agents requires an understanding of the
complex interplay between nuclear receptors in different regions of the brain and their ability to
regulate the expression of CYP3A enzymes. Further studies of bio-transformed drugs by CYP3A
enzymes in the brain are crucial to designing appropriate therapeutic strategies and preventing
toxicity.
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